Table 3 Adverse events from any cause after PSM

From: Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)

Variable

Combination group (n = 228)

Monotherapy group (n = 228)

Patients with an adverse event from any cause

134 (58.8)

101 (44.3)

 Grade 1 or 2 eventa

98 (43.0)

84 (36.8)

 Grade 3 eventa

33 (14.5)

17 (7.5)

 Grade 4 eventa

3 (1.3)

0

 Grade 5 eventa

0

0

Discontinuation of anti-PD-(L)1 therapies

13 (5.7)

N/A

Discontinuation of molecular targeted therapies

27 (11.8)

N/A

Dose interruption of anti-PD-(L)1 therapies

9 (3.9)

N/A

Dose reduction or interruption of molecular targeted therapies

22 (9.6)

N/A

  1. PSM propensity score matching, PD-1 programmed death 1, PD-L1 programmed death ligand 1, N/A not applicable
  2. Data are n (%)
  3. aNumbers represent the highest grades assigned
Back to article page